- BPC-157 and TB-500 anchor the recovery conversation on deep preclinical files, but neither has indexed controlled human trials, and sex-stratified reporting is essentially absent for both.
- TB-500 is studied for actin binding and cell-migration mechanisms central to wound-healing research models, all in preclinical and in-vitro systems rather than human sex-analyzed trials.
- Neither recovery peptide has pregnancy, lactation, or hormonal-interaction data, and BPC-157 dosing figures online are extrapolated from male-animal studies.
The recovery and tendon corner of peptide research is built on two names, BPC-157 and TB-500. Both have deep, legitimate preclinical files describing plausible tissue-repair mechanisms. Both also stop well short of the human, sex-analyzed evidence that would let anyone say what they do in women, or in people at all. That contrast, preclinical depth against clinical and female shallowness, is the whole story of this category.
Two peptides, overlapping repair biology
BPC-157 is a synthetic pentadecapeptide derived from a gastric-juice protein sequence, studied in preclinical models for its relationship to angiogenesis, growth-factor signaling, and the nitric-oxide system, most often in rodent tendon, muscle, and gut injury protocols. TB-500 is a synthetic peptide based on the active region of thymosin beta-4, an actin-binding protein, and has been studied for its role in regulating actin polymerization, cell migration, and cytoskeletal dynamics, processes central to wound-healing and tissue-remodeling models. Different mechanisms, adjacent goals, and both firmly in the laboratory.
| Compound | Studied mechanism | Evidence stage | Human trials indexed |
|---|---|---|---|
| BPC-157 | Angiogenesis, growth-factor and nitric-oxide signaling | Preclinical (rodent injury models) | None |
| TB-500 (thymosin beta-4) | Actin binding, cell migration, cytoskeletal dynamics | Preclinical and in-vitro | None |
Recovery forums circulate specific BPC-157 and TB-500 numbers. Those figures come from animal studies, and neither compound has an established human dose. This site reports dose information only as it appears in the research literature, does not publish personal dosing, and offers no protocol. Nothing here is medical advice.
Why the female gap matters more for athletes
Tendon and connective-tissue biology is known in the sports-science literature to interact with hormonal fluctuations across the menstrual cycle, which makes the total absence of cycle-phase data here especially relevant. For both compounds every female-evidence field returns unstudied: no menstrual cycle interaction data, no hormonal interaction data, no perimenopausal or menopausal data, and no pregnancy or lactation safety data. The recovery narrative aimed at active women is therefore running on mechanism plausibility and male-weighted animal work, not on anything measured in female subjects.
Reading these claims honestly
Everything credible about BPC-157 and TB-500 is a mechanism these compounds have been studied for in preclinical models. None of it is a demonstrated human recovery outcome, and none of it is described that way here. The mechanism data is real, which is exactly why the missing pieces, human trials and any sex-stratified reporting, deserve to be named rather than glossed over.
Recovery peptides are the clearest case on this site of a strong preclinical file sitting on top of an empty female record. If you want each compound's full evidence states, cycle and pregnancy notes, and derived grade, the BPC-157 and TB-500 profiles track how many of the underlying studies included women.